Recent Updates
Recently added Catalysts
ACIU

AC Immune And Takeda Sign Exclusive Option And License Agreement For Active Immunotherapy Targeting Amyloid Beta For Alzheimer s Disease

Monday, May 13, 2024 1 min read
Key Takeaway: AC Immune And Takeda Sign Exclusive Option And License Agreement For Active Immunotherapy Targeting Amyloid Beta For Alzheimer s Disease

Full Press Release Details

AC Immune And Takeda Sign Exclusive Option And License Agreement For Active Immunotherapy Targeting Amyloid Beta For Alzheimer s Disease.
Tags: ACIU Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: May 13, 2024